Sandimmun 50mg Soft Capsules
*Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 20 June 2023
File name
Sandimmun 50mg capsules_REG SPC_PF22-0134_08.06.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 20 June 2023
File name
Sandimmun capsules_REG PIL_PF22-0134_08.06.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
Updated on 11 January 2023
File name
Sandimmun capsules_REG PIL_PF22-0183_09.01.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 11 January 2023
File name
Sandimmun 50mg capsules_REG SPC_PF22-0183_09.01.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 28 July 2022
File name
Sandimmun capsules_REG PIL_PF22-0077_26.07.2022_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
Updated on 28 July 2022
File name
Sandimmun 50mg capsules_REG SPC_PF22-0077_26.07.2022_clean_IPHA.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 21 December 2021
File name
Sandimmun SC_REG PIL_PF21-0206_Nov 2021_clean_typo corrected.pdf
Reasons for updating
- Correction of spelling/typing errors
Updated on 25 November 2021
File name
Sandimmun SC_REG PIL_PF21-0206_Nov 2021_clean.pdf
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
Updated on 31 March 2021
File name
Sandimmun 50mg SC_REG SPC_PF 20-0200_March 2021_IPHA.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 31 March 2021
File name
Sandimmun SC_REG PIL_PF 20-0200_Clean.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
Updated on 19 March 2020
File name
Sandimmun CapsREG PIL PF 19-0253 March 2020.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
Updated on 19 March 2020
File name
Sandimmun 50mg Soft Capsules REG SPC PF19-0253 March 2020 clean.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 03 January 2020
File name
Sandimmun Soft Capsules REG PIL 46238042 August 2018_IPHA.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 23 January 2019
File name
IPHA_sandimmunscapsulesPIL_46238042_IE_REG REV TBI 6 Jan 2019.pdf
Reasons for updating
- Change of manufacturer
- Change to date of revision
- Change to marketing authorisation holder
Updated on 09 August 2018
File name
REG_SPC_Sandimmun 50mg Soft Capsules REG SPC_PF18-0228_clean.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 17 September 2015
File name
PIL_8556_391.pdf
Reasons for updating
- New PIL for new product
Updated on 17 September 2015
Reasons for updating
- Change to side-effects
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 25 June 2015
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 25 June 2015
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.8 has been updated to include "pain of lower extremities" as an adverse event of unknown frequency.
Updated on 29 September 2014
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change due to harmonisation of SPC
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 24 September 2014
Reasons for updating
- Change to date of revision
- Change due to harmonisation of PIL
Updated on 08 January 2013
Reasons for updating
- Change to warnings or special precautions for use
Updated on 23 November 2012
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Sections 4.4 and 4.8 have been updated to specifically describe PML and BK virus nephropathy in the general statement on infections in patients receiving immunosuppressive therapies.
Section 5.1 has beeen updated to include a sentence about the use of ciclosporing in liver transplant patients HCV+ and HCV-.
Updated on 19 September 2012
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.1 - List of excipients
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
- Correction of spelling/typing errors
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 April 2007
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 06 December 2006
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 26 October 2006
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Changes to Section 4.1 (Therapeutic Indications), Section 4.2 (Posology and Method of Administration), Section 4.4 (Special Warnings and Precautions for Use), Section 4.5 (Interactions with other Medicaments and other forms of Interaction,) Section 4.6 (Pregnancy and Lactation), Section 4.8 (Undesirable Effects), Section 4.9 (Overdose), Section 5.1(Pharmacodynamic Properties), Section 5.2 (Pharmacokinetic Properties) and, Section 5.3 (Preclinical Safety Data) following an update to the company core data sheet
Updated on 26 June 2006
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 17 May 2005
Reasons for updating
- Improved electronic presentation
Updated on 26 August 2004
Reasons for updating
- New PIL for medicines.ie